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ABSTRACT Malaria persists as a major health problem due to the spread of drug re-
sistance and the lack of effective vaccines. DNA gyrase is a well-validated and extremely
effective therapeutic target in bacteria, and it is also known to be present in the apico-
plast of malarial species, including Plasmodium falciparum. This raises the possibility that
it could be a useful target for novel antimalarials. To date, characterization and screen-
ing of this gyrase have been hampered by difficulties in cloning and purification of the
GyrA subunit, which is necessary together with GyrB for reconstitution of the holo-
enzyme. To overcome this, we employed a library of compounds with specificity for P.
falciparum GyrB and assessed them in activity tests utilizing P. falciparum GyrB together
with Escherichia coli GyrA to reconstitute a functional hybrid enzyme. Two inhibitory
compounds were identified that preferentially inhibited the supercoiling activity of the
hybrid enzyme over the E. coli enzyme. Of these, purpurogallin (PPG) was found to dis-
rupt DNA binding to the hybrid gyrase complex and thus reduce the DNA-induced ATP
hydrolysis of the enzyme. Binding studies indicated that PPG showed higher-affinity
binding to P. falciparum GyrB than to the E. coli protein. We suggest that PPG achieves
its inhibitory effect on gyrase through interaction with P. falciparum GyrB leading to dis-
ruption of DNA binding and, consequently, reduction of DNA-induced ATPase activity.
The compound also showed an inhibitory effect against the malaria parasite in vitro
and may be of interest for further development as an antimalarial agent.
KEYWORDS DNA gyrase, antimalarial agents, apicomplexan parasites, apicoplast,
fluoroquinolones, purpurogallin, supercoiling, topoisomerases
DNA gyrase is a type II topoisomerase that performs essential topological opera-tions on DNA and has the unique ability to carry out negative supercoiling by
using energy provided by ATP hydrolysis (1). In addition, gyrase is a well-known, effec-
tive, and widely used antibacterial drug target (2, 3). Along with topoisomerase IV, it is
the target of the broad-spectrum fluoroquinolone class of antibacterials, which are
used to treat a variety of infections, most notably those of the urinary tract. Its attrac-
tiveness as a drug target is increased by the lack of a gyrase enzyme in human cells.
Gyrase is composed of two subunits, GyrA and GyrB, with the functional enzyme
being an A2B2 tetramer. Its mechanism of action and the relationship between struc-
ture and function have been well characterized (2) (Fig. 1A). Gyrase is thought to
bind to a section of DNA known as the G-segment, which binds across the GyrA
dimer interface (the saddle region). The G-segment is cleaved across both strands
via formation of a phosphotyrosine bond with the active site tyrosines in the GyrA
dimer. For negative supercoiling to occur, the DNA must be wrapped around gyrase
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with positive handedness, and this wrap is achieved by the C-terminal domains of
GyrA which form a six-bladed b-propeller. Another section of the same double-
stranded DNA (dsDNA), the “T-segment,” is then captured by the N terminus of
GyrB (the “DNA clamp,” which dimerizes upon binding of ATP), passed through the
FIG 1 Overview of the bacterial gyrase-mediated DNA negative supercoiling catalytic cycle and a schematic showing the domain
organization of E. coli and P. falciparum gyrases. (A) The EcGyr-mediated DNA supercoiling cycle. (i) DNA binds to EcGyr with EcB
capturing the T-strand. (ii) ATP binding to EcB. (iii) ATP hydrolysis by EcB to facilitate the strand passing. Novobiocin inhibits
gyrase by competing for binding with ATP. (iv) DNA religation. This step is inhibited by gyrase poisons (e.g., CIP and thiophene),
both of which achieve stabilization of the gyrase-cleaved DNA complex. (v) ATP hydrolysis for structural rearrangement and
subsequently release of the DNA substrate. (B) Illustration of gyrase domains. Domain information was retrieved from Pfam (45). It
has previously been noted (21, 31) that Pfam predicts only three blades in PfGyrA_CTD, but at least two further putative blades
have been identified (31). The domains and their sizes are labeled accordingly.
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break generated in the G-segment, and finally is released through the “bottom”
gate in GyrA.
Bacterial gyrase is the target of a number of antibacterial drugs (4). Most notable
are the aminocoumarins and the fluoroquinolones (5). The latter is an extremely impor-
tant class of drugs that function by binding to the gyrase-DNA complex at the stage
where both DNA strands are cleaved (6), a mechanism shared by the thiophenes.
These compounds allosterically stabilize the cleavage complex through binding to ei-
ther one or two DNA strands (7). Stabilization of the cleavage complex eventually
results in fragmentation of the bacterial genome and cell death. Aminocoumarins,
such as novobiocin, function differently in that they compete with ATP for binding to
the ATP binding site in the N-terminal region of GyrB (2, 8).
Gyrase was initially discovered as a bacterial enzyme (9) but later confirmed as
being present in some plants (10–12), Plasmodium spp., and other members of the
Apicomplexa. The genes of apicomplexan protozoan gyrase are contained in the nu-
clear genome, but the functional DNA gyrase is present in a plastid called the apico-
plast (13, 14). The apicoplast is a four-membraned organelle found in some protozoa
(15). It is a result of secondary endosymbiosis wherein a prokaryotic cyanobacterium
was incorporated into a eukaryote and subsequently engulfed by another eukaryote
(16). It is indispensable due to its important role in biosynthesis of fatty acid, isopre-
noids, iron-sulfur clusters, and heme (17). Due to its bacterial origin, it retains a circular
genomic DNA that requires the nucleus-encoded gyrase to resolve topological chal-
lenges (18). To date, little characterization of apicoplast gyrases has been carried out
(19, 20). Bioinformatics analyses suggest that Plasmodium falciparum GyrA (PfA) and P.
falciparum GyrB (PfB) retain the expected domain structure as well as the conserved
catalytic residues (18, 21). Interestingly structure prediction tools predict fewer than
the expected number of propellers in the b-propeller domain. These gyrases are con-
siderably larger than other characterized gyrases, containing stretches of additional
unannotated sequences, the functions of which are currently unclear (21) (Fig. 1B; see
Fig. S1A and B in the supplemental material).
Given the effectiveness of gyrase as a lethal bacterial target, its presence in
Plasmodium spp. immediately raises the prospect of using apicoplast gyrase as a novel
antimalarial target as well as in toxoplasmosis given that gyrase is also necessary for
apicoplast genome replication and parasite growth in Toxoplasma gondii (22). The pat-
tern of conservation between apicoplast and well-characterized prokaryotic gyrases
suggests that binding sites for gyrase-targeting antibacterials are likely to remain
highly similar. An apicoplast gyrase-targeting agent should have few side effects given
that gyrase does not occur in humans (18). Indeed, antibacterials have been used
against the parasite, including gyrase-targeting ciprofloxacin (CIP), which results in a
“delayed death” phenomenon as a result of arresting of growth in the second asexual
cycle (23). Among fluoroquinolones tested, CIP has been reported as having best anti-
malaria activity but had off-target (i.e., non-gyrase/topoisomerase IV) toxicity, which
may have been partially responsible for the killing effect observed (24–26). In contrast,
other reports have shown that fluoroquinolones do not appear to be particularly effec-
tive antimalarial agents against uncomplicated malaria and suggested they should be
used together with other standard antimalarials (27, 28). Furthermore, targeting
malaria with antibacterials such as gyrase poisons may not be wise, as it would have
the potential to accelerate the spread of antibacterial resistance (29).
For these reasons, we have attempted to discover new molecules that specifically
inhibit malarial apicoplast gyrase but not bacterial gyrase. As P. falciparum causes the
most severe outcomes among all Plasmodium species (24, 30), we chose to work with
P. falciparum gyrase (PfGyr) proteins. To test for inhibitors, it is necessary to produce
purified PfGyr for in vitro experiments. Unfortunately, it has not yet proven possible to
express and purify functional PfA (31). However, expression and purification of PfB
have been reported (20, 32). PfB is known to be able to form an active, supercoiling-
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competent gyrase complex with Escherichia coli GyrA (EcA), while its intrinsic ATPase
activity can be induced by the addition of DNA (20).
We have cloned and purified the recombinantly expressed PfB and reconstituted a
hybrid gyrase by combining it with EcA (EcA2PfB2). This was tested against a chemical
library consisting of 98 compounds selected from a screen for molecules that bind to
PfB but not EcB. Those hit compounds were then characterized in further functional
assays, including ATPase activity, supercoiling, and DNA cleavage activity. This has
resulted in the isolation of two candidates. Of these, purpurogallin (PPG) {3,9,10,11-tet-
rahydroxybicyclo[5.4.0]undeca-1(7),3,5,8,10-pentaen-2-one} was found to be the most
promising and was characterized further.
RESULTS
P. falciparum gyrase production and purification. To fully characterize PfGyr, it
would be necessary to reconstitute the holoenzyme. However, attempts to produce the
full PfGyr complex were not successful due to difficulties in PfA production, even after
extensive trials, consistent with the previous report (20). In contrast, full-length (without
the predicted signal peptide) mature PfB production was achieved, as reported in previ-
ous studies (Fig. S1C). PfB exists as a homodimer and can assemble a functional gyrase
complex with EcA (20). In addition, this hybrid complex is sensitive to known bacterial
gyrase inhibitors, including CIP and novobiocin, although sensitivity to the former is less
than that seen for EcGyr (Fig. S1D and E).
Screening reveals small compounds able to specifically inhibit supercoiling
activity of PfB-containing gyrases. We used a chemical library consisting of 98 com-
pounds selected based on preferential binding to PfB over the bacterial EcB protein.
We further screened this library against the supercoiling activity of the hybrid enzyme
(see Fig. S2A in the supplemental material). Two compounds showing significant inhi-
bition were identified: PPG and alizarin red S (ARS) (1,2-dihydroxy-3-(oxysulfonyl)-9,10-
anthracenedione) (Fig. S2A in the supplemental material; lane A10 is PPG, and lane B6
is ARS). PPG specifically inhibited the supercoiling activity of the hybrid gyrase (50% in-
hibitory concentration [IC50], 9.566 1.94mM) but not that of bacterial gyrase (IC50,
.1,000mM) (Fig. 2A and Table 1). Similarly, ARS also preferentially inhibited the hybrid
gyrase (IC50, 55.596 6.74mM) (Fig. 2B and Table 1). PPG, compared to ARS, showed
better efficacy in inhibiting the hybrid gyrase supercoiling ability. We then focused on
characterizing PPG-mediated inhibition both in vivo and in vitro in this study.
PPG decreases the DNA-enhanced ATP hydrolysis rate of PfB. Given that PPG
was identified based on binding to an EcA2PfB2 complex in preference to a EcGyr com-
plex, we hypothesized PfB as the most likely binding site. We tested PPG binding to PfB
and EcB using microscale thermophoresis (MST). MST profiles showed that PPG binding
to both GyrB proteins followed a sigmoidal shape. The curve for PfB (dissociation constant
[Kd], ;1.036 0.11mM) was steeper than that for EcB (Kd, ;4.546 0.39mM), which indi-
cates tighter binding in the case of PfB (Fig. 3A). Because the MST curves fitted a sigmoi-
dal 1:1 binding model, it also suggests that one PPG is bound per monomer (two PPGs
per PfB dimer). Next, we investigated the effects of PPG’s interaction with PfB. It has been
reported that PfB alone has intrinsic ATP hydrolysis activity, and this activity can be
enhanced by the presence of DNA (20). We performed ATP hydrolysis assays and deter-
mined the effect of PPG on PfB activity. As expected, the intrinsic ATP hydrolysis activity
of PfB, in the absence of the A subunit, was increased around 3-fold by the addition of
DNA (Fig. 3B). The addition of PPG decreased this DNA-enhanced ATP hydrolysis of PfB in
a dose-dependent manner, while the intrinsic ATPase activity remained unchanged. We
further observed that PPG treatment also inhibited the DNA-induced ATPase activity of
EcA2PfB2, although this was more modest (Fig. 3C). On the other hand, both intrinsic ATP
hydrolysis and enhanced ATP hydrolysis by EcB in the complex with EcA were little
affected by the presence of PPG. Overall, these results suggest that the PPG mechanism
of action is distinct from those of competitive ATP binders, such as novobiocin, and likely
acts via interaction with a different site on GyrB.
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PPG decreases DNA binding to PfB. The effect of PPG on DNA-stimulated ATPase
activities of PfB and EcA2PfB2 suggested a possible mechanism whereby DNA binding
is inhibited. To test that hypothesis, gel-based DNA binding assays were performed in
which the binding of PfB and DNA was observed as a shift of the DNA band. In this
case, the shifted PfB-DNA complex was not able to enter the gel even after extensive
optimization trials—possibly due to the overall charge of the complex. In contrast, the
DNA-EcA2PfB2 complex was visible as a shifted band on the gel. To investigate the
effect of PPG on the DNA binding ability of proteins, PPG was added to the reaction
with EcA2PfB2 and PfB alone (Fig. 4). We found that formation of the DNA-PfB complex
was inhibited at approximately 20mM PPG and was observed as the appearance of the
free DNA fragment in the gel (Fig. 4A). Furthermore, the DNA-EcA2PfB2 complex was
similarly disrupted at 10 mM PPG, and the interaction was completely abolished at 40
mM PPG (Fig. 4B). In contrast, the DNA-EcGyr complex remained intact in the presence
TABLE 1 IC50 of compounds in supercoiling inhibitory activity
Antimalarial drug
IC50 (mM) for target:
EcGyr EcA2PfB2
CIP 0.916 0.33 7.066 0.76
Novobiocin 1.046 0.22 1.836 0.39
PPG .1,000 9.566 1.94
ARS .100 55.596 6.74
FIG 2 PPG and ARS preferentially inhibit EcA2PfB2 DNA supercoiling. (A and B) Chemical structures of PPG and ARS are shown (top).
Representative gel images of DNA supercoiling by hybrid gyrase or EcGyr against PPG or ARS (middle). Concentrations of inhibitors are as
labeled above the lanes. Cartoons to the right of gels indicate the topological state of the corresponding bands on the gels, being open
circular (circle), relaxed (R), or negatively supercoiled (helix). Plots summarizing multiple experiments (n= 3), including hybrid gyrase (black
circles) and EcGyr (gray triangles), are shown below the relevant gels, and the standard deviation (SD) is plotted on the graphs. PPG and ARS
were dissolved in DMSO, and the final DMSO concentration in the assay was 1%.
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of PPG (Fig. 4C). In addition, we did not observe any linear DNA formation by PPG
treatment using the DNA cleavage assay. This observation suggests that PPG inhibits
interactions with DNA either directly or via GyrA-GyrB complex destabilization rather
than stabilizing the protein cleaved-DNA complex (Fig. S2B).
PPG inhibits growth of P. falciparum.We further investigated the effect of PPG on
P. falciparum survival rates in vitro. PPG was found to negatively affect the growth of P.
falciparum (3D7) in vitro. The growth-inhibitory IC50 of PPG on P. falciparum was
926 16mM after 96 h of treatment (Table 2). This IC50 is comparable to those of other
tested compounds, such as quinolones or ENT1 inhibitors (25, 33–35), which range
from 5 to 100mM. Although the efficacy of PPG at inhibiting P. falciparum growth is
not as high, the fact that it is specific to the P. falciparum protein suggests it may offer
a useful basis for further development of P. falciparum or apicomplexan-specific gyrase
inhibitors.
DISCUSSION
The discovery of new drugs effective in treating malaria is an important ongoing
challenge. P. falciparum DNA gyrase offers a new potential target given the likelihood
that its inhibition will have a negative effect on parasite growth (25). Screening and
testing of potential PfGyr-specific inhibitors would ideally be carried out against the
FIG 3 PPG interaction with GyrB subunits and its influence on DNA-induced ATP hydrolysis of PfB, the hybrid complex,
and EcGyr. (A) PPG binds to PfB preferentially in comparison to EcB. Fluorescently labeled proteins were incubated with
titrated PPG, and then samples were measured using MST. The curve presented on the graph represents fitting with a
1:1 binding curve. (B to D) PPG influence on DNA-induced ATP hydrolysis activity for PfB (B), EcA2PfB2 (C), or EcGyr (D).
The final DMSO concentration was 1%. n= 3. The standard error (SE) is plotted in the graph.
FIG 4 PPG specifically abolished DNA binding to EcA2PfB2 and PfB. (A to C) EMSA showing the effect of increasing amounts of PPG in retarded migration
of the DNA band caused by binding to gyrase proteins. Results are shown for PfB (A), EcA2PfB2 (B), or EcGyr (C). DNA (147 bp) was stained with SYBR gold
for visualization. The final DMSO concentration was 1%.
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native A2B2 complex. However, as noted, full-length PfA production has not proven
possible to date. Similar problems have been observed for the other characterized api-
complexan gyrase from T. gondii, where only minimal amounts of GyrA could be puri-
fied and tested (19). It is notable that in both cases, the GyrA proteins in question are
thought to contain significant stretches of additional amino acids compared to other
known GyrAs, and these are predicted to be flexible, hinting at misfolding as a possible
cause of the observed reduced expression (21). Others have shown that truncated
forms of PfA (amino acids [aa] 163 to 540, lacking the C-terminal DNA-wrapping
domains) can form complexes with cognate, full-length PfB. The resulting complexes
were shown incapable of carrying out supercoiling but were able to form cleavage
complexes in the presence of both calcium and fluoroquinolone (20). In our hands,
however, we were unable to recapitulate the previously observed cleavage results.
We have noticed that PfB can support EcA to carry out supercoiling reactions.
Interestingly supercoiling by the hybrid enzyme was shown to be approximately 10-
fold less sensitive to CIP than the E. coli gyrase (Fig. S1E). While the majority of fluoro-
quinolone resistance mutations in gyrase map to the region of GyrA close to the cata-
lytic tyrosine, some are known to map to GyrB (36) in the Toprim domain. Notably, PfB
has an approximately 45-aa insert close to this region of the Toprim domain (32), rais-
ing the possibility that this may be responsible for additional interactions and/or struc-
tural features that have an inhibitory effect on fluoroquinolone binding.
In this work, we have shown that PPG has an inhibitory effect specific to EcA2PfB2, in
contrast to EcGyr. This was demonstrated in decreased supercoiling activity and
decreased DNA binding by the hybrid enzyme in the presence of PPG. PfB has a unique
feature in that its ATP hydrolysis can be enhanced by DNA binding (20). ATPase results
with PfB were consistent with PPG decreasing binding to DNA as the DNA-stimulated
activity was reduced in the presence of PPG, while DNA-independent activity was
largely unaffected (Fig. 3B). The effect on the DNA-stimulated ATPase activity of
EcA2PfB2 was less significant than on PfB and only slightly greater than on EcGyr (Fig.
3C and D). Interestingly, in the context of the EcA2PfB2 complex, PPG decreased the
ATPase activity in both the absence and presence of DNA (Fig. 3C). PfB is substantially
larger than the prokaryotic homologs and includes significant extra sequences in the
Toprim domain (21). It is quite possible that in the context of the hybrid enzyme, the
bacterial GyrA interacts with some of these unique features in PfB either to mildly stim-
ulate ATPase activity (and this stimulation is lost through conformational change upon
high-concentration PPG treatment) or, conversely, that PPG causes a conformational
change in PfB that acts to inhibit intrinsic ATPase activity. In contrast, EcA2PfB2 binding
to DNA appeared to show a greater apparent sensitivity to PPG (complete loss of bind-
ing at 5 to 10mM PPG, while DNA-stimulated ATPase is only significantly reduced at 25
to 50mM PPG). This likely reflects the lower-affinity binding of the 147-bp DNA used in
the electrophoretic mobility shift assays (EMSAs), which is insufficient for full node for-
mation (37, 38).
How PPG achieves inhibition of DNA binding is still unclear. Our MST results and
ATPase results demonstrate that the PPG is capable of achieving binding and ATPase
inhibition through interaction with PfB alone in the absence of GyrA. This suggests the
possibility of a PPG binding pocket unique to PfB that is able to interfere with DNA
TABLE 2 IC50 of compounds for inhibition of P. falciparum growth in vitro
Antimalaria
drug(s)
IC50 in P. falciparum
3D7 Proposed target Reference(s)
PPG 926 16mM PfGyr This study
CIP 36 0.5mM PfGyr and off-target effect 25, 33
Quinolines 20–100mM Gyrase poisoning 25
ENT1 inhibitors 5–50mM PfENT1 34
Acriflavine 5mg/kg DNA replication foci in parasite/indirect decrease in PfGyr activity by
interaction with DNA substrate
35
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binding. As already mentioned, PfB has significant additional stretches of amino acids
compared to bacterial homologs. These extra regions may regulate some functions of
the enzyme, providing a target for inhibitors that is not present in the prokaryotic
enzyme. One possible mechanism whereby inhibition by PPG could be achieved would
be for the binding of PPG to PfB to destabilize the GyrA-GyrB interface. Thus, it could in
turn lead to the observed effect on DNA binding. To further understand PPG’s action
on PfB, we have tried extensive cocrystallization trials of PfB and PPG but have been
unable to obtain any crystals to date.
Tests of the effect of PPG on P. falciparum growth showed moderate inhibitory efficacy
and raise the question of whether the observed inhibition in vivo is due to the observed in
vitro effects on DNA gyrase and will require significant future work to answer. As PPG does
not appear to act as a gyrase poison, it is unlikely to be as potent against P. falciparum as
poisons such as fluoroquinolones are against many prokaryotic gyrases. However, it is inter-
esting to note that even moderately effective inhibitors may have a role as part of artemisi-
nin-based combination therapies when combined with artemisinin (39, 40). Clearly, targeting
enzymes within the apicoplast represents a challenge given the large number of mem-
branes any therapeutic would have to pass through in order to reach the target. This may
require the development of appropriate nanoparticle delivery systems (41, 42).
MATERIALS ANDMETHODS
Protein production and purification. The full-length PfB open reading frame (ORF) (3D7; accession
no. Q8I528) was synthesized as a codon-optimized sequence for use in E. coli expression systems. The N-
terminal fragment (aa 1 to 120) was omitted when subcloning to the expression vectors as it is predicted
to be a signaling peptide and not to be present in mature, functional forms of PfB (31). The mature PfB
ORF (aa 121 to 1006) was amplified and cloned to a pET28a1 vector (Genscript, Inc., USA) using NdeI
and BamHI restriction enzymes. The plasmid was transformed to BL21(DE3) Gold competent cells
(Agilent) and cultured in LB medium at 37°C. When the optical density at 600 nm (OD600) reached 0.6,
0.25mM isopropyl-b-D-thiogalactopyranoside (IPTG) was added to induce protein expression, and cells
were cultured overnight at 18°C with shaking. Cells were collected by centrifugation.
Purification of gyrase proteins was carried out using published methods as a guide (43). For PfB protein,
the cell pellet was suspended in lysis buffer containing 50mM Tris-HCl (pH 7.5), 150mM NaCl, 20mM imid-
azole, 10% glycerol, protease inhibitor cocktail (Pierce EDTA-free protease inhibitor tablets; Thermo), and
0.1% Triton X-100. Cells were further lysed by sonication, and the supernatant was separated from insoluble
pellet by centrifugation at 50,000  g for 30min at 4°C. The clear supernatant was loaded onto a HisTrap
column (5ml; GE Healthcare), and bound proteins were eluted in the lysis buffer containing 250mM imidaz-
ole. The eluted fractions were desalted on desalting columns (GE Healthcare) and loaded onto a Mono Q
16/10 ion-exchange column (GE Healthcare) which was equilibrated in TGED buffer (50mM Tris-HCl [pH
7.5], 1mM EDTA, 2mM dithiothreitol [DTT], 10% glycerol). Protein was eluted using a linear gradient of 0.1
to 1 M NaCl gradient in TGED buffer. The pooled protein fractions were concentrated and loaded onto a
Superdex 200 16/600 (GE Healthcare) column equilibrated in TGED for gel filtration. The protein was col-
lected, concentrated, snap-frozen in liquid nitrogen, and stored at280°C.
DNA supercoiling. A supercoiling assay was utilized to test a library of compounds previously
selected for binding to EcA2PfB2 but not EcGyr. The library was a kind gift from Yasumitsu Kondoh,
RIKEN. The EcGyr complex was used as a control allowing selection for specific compounds that target
PfB. Supercoiling assays were carried out in a buffer consisting of 35mM Tris-HCl (pH 7.5), 24mM KCl,
4mM MgCl2, 2mM DTT, 1.8mM spermidine, 1mM ATP, 6.5% (wt/vol) glycerol, and 0.1mg/ml bovine se-
rum albumin (BSA). The hybrid (EcA2PfB2) complex or EcGyr complex was formed in the storage buffer
(50mM Tris-HCl [pH 7.5], 100mM KCl, 10% [wt/vol] glycerol, 1mM EDTA, 2mM DTT). In a 30-ml reaction,
the gyrase complex and 0.5mg of pBR322 relaxed DNA (Inspiralis, United Kingdom) were assembled on
ice and incubated at 37°C for 30min. The reaction was then stopped by adding an equal volume of stop
solution (40% sucrose, 100mM Tris-HCl [pH 7.5], 1mM EDTA, 0.5mg/ml bromophenol blue) and
extracted by mixing with 30ml chloroform-isoamyl alcohol (24:1). The samples were centrifuged at
14,000  g for 1min, and the aqueous phase was collected and loaded onto a 1% 1 Tris-acetate-EDTA
(TAE) agarose gel. The DNA products were resolved by electrophoresis at 80 V for 120min and visualized
by UV irradiation. The images were then analyzed using ImageJ v.1.47 to obtain the intensity of the
supercoiled DNA band. Gyrase with 1% dimethyl sulfoxide (DMSO) was used as the control. The percent-
age of supercoiled DNA (% SC) was normalized using samples with gyrase in the absence of inhibitor as
the full supercoiling control and was plotted against PPG concentration. Data were fitted to the equa-
tion % SC = aeb[PPG], where a and b are function parameters, using OriginLab Origin (Pro) v.2020b. The
IC50 (concentration of PPG required for 50% supercoiling inhibition) was calculated from the fitted func-
tion IC50 (concentration of PPG required for 50% supercoiling inhibition).
Microscale thermophoresis. Microscale thermophoresis (MST) experiments were performed using a
Monolith NT.115 instrument (NanoTemper). Proteins (PfB and EcB) were labeled with Red 2nd Generation
labeling kits (NanoTemper) in which the fluorescent red dye was coupled with protein via NHS coupling.
Labeled protein (100nM) was mixed with PPG (Activate Scientific, dissolved in DMSO to a final
Pakosz et al. Antimicrobial Agents and Chemotherapy













































concentration of 5%) and in MST buffer {240mM NaPi (pH 7.4), 274mM NaCl, 54mM KCl, 100mM TCEP [Tris
(2-carboxyethyl)phosphine hydrochloride], 0.05% Tween 20, 5% DMSO} and incubated in the dark for 15
min. The samples were applied onto capillaries (Monolith NT.115 MST Premium coated capillaries), and the
fluorescence signal was measured using MO.Control software (Nanotemper). Initial fluorescence signal was
used for binding analysis, and Kd was calculated using 1:1 binding model. Results were baseline corrected
and normalized for amplitude using MO.Control software (Nanotemper). The Kd values were calculated
based on three independent measurements. All experiments were performed at room temperature.
ATPase activity. The ATP hydrolysis reaction was performed as follows. Enzyme was incubated in
the assay buffer (50mM Tris-HCl [pH 7.5], 125mM KCl, 1mM EDTA, 5mM MgCl2, 5mM DTT, 10% glyc-
erol) with test compounds at various concentrations, 1mM ATP, and 10.5 nM linear pBR322 DNA for
30min at room temperature. The protein concentrations used in the assay were as follows: 1mM PfB,
0.5mM EcA2PfB2, and 100 nM EcGyr. A malachite green assay kit (Sigma-Aldrich) was used to measure
the released phosphate in the reaction. In brief, malachite green reagent was added to the reaction mix-
ture, and the mixture was further incubated for 10min. The formed color was measured at 620 nm using
a plate reader (SpectraMAX190; Molecular Devices). The amount of released phosphate was calculated
based on a calibration curve covering a linear range of 50 to 250 pmol using eight concentrations, which
was prepared for each measurement independently. Experiments were carried out in triplicate.
Electrophoretic mobility shift assay. DNA binding assays were carried out using electrophoretic
mobility shift assay (EMSA) with 147 bp dsDNA (based on the preferred gyrase cleavage site from plas-
mid pBR322) (31). In brief, 20 nM DNA was mixed with 200 nM reconstituted complex (hybrid or EcGyr)
or 1mM PfB in an assay buffer (30mM Tris-HCl [pH 7.5], 75mM KCl, 2mM MgCl2, 6% glycerol, 1mM DTT)
and PPG for 1 h at room temperature. The samples were resolved in a 5% polyacrylamide gel in TBM
buffer (90 mM Tris-borate, pH 7.5, 4 mM MgCl2) for 1 h at 80 V. The gel was stained with SYBR gold
(Thermo) and visualized under UV light.
Activity against Plasmodium falciparum. Tests on parasites were performed by Anti-infectives
Screening Core Services at NYU School of Medicine based on previously published protocol (44). P. falcipa-
rum strain 3D7 was used for all determinations. Using 96-well plates, 100ml of P. falciparum growth medium
(RPMI 1640, 25mM HEPES, 0.1mg/ml gentamicin, 0.05mg/liter hypoxanthine [pH 6.75]), supplemented
with 0.25% sodium bicarbonate and 0.5% Albumax II (Invitrogen), was added to each well. A 10mM stock
of PPG in DMSO was then serially diluted in triplicate. DMSO at the highest concentration used (0.5%) was
tested in parallel as a control. Asynchronous P. falciparum in a 100-ml volume was then added to each well
at 0.25% late-stage parasitemia with 5% hematocrit, as well as controls (medium, red blood cells, P. falcipa-
rum, or P. falciparum with 2mM chloroquine). The plates were placed in a sealed chamber and maintained
under atmospheric conditions of 5% oxygen, 5% carbon dioxide, and 90% nitrogen at 37°C for 96 h. To
determine the cell viability, a SYBR green assay for rapid assessment was performed.
After incubation, plates were placed at 280°C for 24 h. The plates were then thawed at 37°C for 4 h.
Once thawed, 100ml of from each resuspended well was transferred into a black, 96-well plate. To each
well, 100ml of a solution containing 0.2ml of SYBR green I nucleic acid dye (Molecular Probes) in 1ml of lysis
buffer (20mM Tris-HCl [pH 7.5], 5mM EDTA, 0.008% saponin, 0.08% Triton X-100) was added. The plates
were covered in aluminum foil, followed by incubation on a plate shaker for 1 h at room temperature.
Plates were analyzed on a fluorescence plate reader (Victor) at excitation and emission wavelengths of 485
and 530nm, respectively. The counts were plotted against the logarithm of the PPG concentration, and
curves were fitted by nonlinear regression. The IC50 was determined as the PPG concentration that pro-
duced 50% of the maximum counts from the drug-free controls. The results are the averages of triplicates.
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